Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Myla D Goldman

Showing results (1-10 of 76) with videos related to

Pageof 8
Sort By:
Continuum (Minneapolis, Minn.)|August 8, 2022
Epidemiology and Pathophysiology of Multiple SclerosisMelanie Ward, Myla D Goldman
JAMA Neurology|September 9, 2015
Smoking Beyond Multiple Sclerosis Diagnosis: A Risk Factor Still Worth ModifyingMyla D Goldman, Olaf Stüve
Neurology|October 29, 2008
Statins to treat multiple sclerosis: friend or foe?Myla D Goldman, Jeffrey A Cohen
Neurology|February 1, 2015
Multiple sclerosis, immunomodulation, and immunizations: balancing the benefitsMyla D Goldman, Robert T Naismith
Expert Review of Clinical Immunology|August 23, 2014
Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis: a review of its clinical pharmacology, efficacy and safetyDavid E Jones, Myla D Goldman
Headache|July 17, 2003
Misdiagnosis of migraineMyla D Goldman, Ivan S Login
Multiple Sclerosis and Related Disorders|July 27, 2016
A study of dietary modification: Perceptions and attitudes of patients with multiple sclerosisJ Nicholas Brenton, Myla D Goldman
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference|March 9, 2017
Relationship between gait variables and domains of neurologic dysfunction in multiple sclerosis using six-minute walk testAsma Qureshi, Maite Brandt-Pearce, Myla D Goldman
Multiple Sclerosis and Related Disorders|April 21, 2015
Vitamin D status and age of onset of demyelinating diseaseJ Nicholas Brenton, Scott Koenig, Myla D Goldman
Innovations in Pharmacy|May 19, 2021
Smoking Cessation Considerations for People with Multiple SclerosisChrista Brooker, Myla D Goldman, S Ross Tingen
Pageof 8

Showing results (1-10 of 76) with videos related to

Sort By:
Pageof 8
Continuum (Minneapolis, Minn.)|August 8, 2022
Epidemiology and Pathophysiology of Multiple SclerosisMelanie Ward, Myla D Goldman
JAMA Neurology|September 9, 2015
Smoking Beyond Multiple Sclerosis Diagnosis: A Risk Factor Still Worth ModifyingMyla D Goldman, Olaf Stüve
Neurology|October 29, 2008
Statins to treat multiple sclerosis: friend or foe?Myla D Goldman, Jeffrey A Cohen
Neurology|February 1, 2015
Multiple sclerosis, immunomodulation, and immunizations: balancing the benefitsMyla D Goldman, Robert T Naismith
Expert Review of Clinical Immunology|August 23, 2014
Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis: a review of its clinical pharmacology, efficacy and safetyDavid E Jones, Myla D Goldman
Headache|July 17, 2003
Misdiagnosis of migraineMyla D Goldman, Ivan S Login
Multiple Sclerosis and Related Disorders|July 27, 2016
A study of dietary modification: Perceptions and attitudes of patients with multiple sclerosisJ Nicholas Brenton, Myla D Goldman
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference|March 9, 2017
Relationship between gait variables and domains of neurologic dysfunction in multiple sclerosis using six-minute walk testAsma Qureshi, Maite Brandt-Pearce, Myla D Goldman
Multiple Sclerosis and Related Disorders|April 21, 2015
Vitamin D status and age of onset of demyelinating diseaseJ Nicholas Brenton, Scott Koenig, Myla D Goldman
Innovations in Pharmacy|May 19, 2021
Smoking Cessation Considerations for People with Multiple SclerosisChrista Brooker, Myla D Goldman, S Ross Tingen
Pageof 8